CHS-114 is under clinical development by Coherus BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CHS-114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CHS-114 overview

CHS-114 is under development for the treatment of solid tumor and head and neck squamous cell carcinoma. The drug candidate is a afucosylated IgG1 antibody acts by targeting chemokine receptor CCR8. It is developed based on ActivMAb antibody discovery platform.

Coherus BioSciences overview

Coherus BioSciences (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats Nasopharyngeal Carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for Hepatocellular Carcinoma and Non-Small Cell Lung Cancer; CHS-114 and CHS-1000, which targets Solid Tumors. The company also develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor and YUSIMRY, a biosimilar to Humiram which treats inflammatory diseasesCoherus is headquartered in Redwood City, California, the US.

For a complete picture of CHS-114’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.